US Patent Issued to Impact Therapeutics (Shanghai) on Jan. 27 for "Crystal forms of 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1H,3H)-dione and preparation thereof" (Chinese Inventors)

ALEXANDRIA, Va., Jan. 28 -- United States Patent no. 12,534,454, issued on Jan. 27, was assigned to Impact Therapeutics (Shanghai) Inc (Shanghai).

"Crystal forms of 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1H,3H)-dione and preparation thereof" was invented by Sui Xiong Cai (Shanghai), Ning Ma (Jiangsu, China), Yisheng Yang (Shanghai) and Kai Yang (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provide crystal forms of 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl) piperazine-1-carbonyl) benzyl) quinazoline-2, 4 (1H,3H)-dione and preparation method thereof."

The patent was filed on Nov. 9, 2021, under Application No. 18/252,423.

*For further information, in...